Imatinib
Imatinib inhibits KIT and PDGFRA and remains first-line therapy for most susceptible advanced GIST.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Stomach, Small Intestine, Others), By Application (Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End Users), By End User (Adult Patients, Pediatric Patients, Geriatric Patients), By Mutation Type (KIT Mutations, PDGFRA Mutations, Wild-Type GIST), By Treatment Modality (Surgery, Targeted Therapy, Other Therapies), and Regional Forecast, 2026-2034
The global gastrointestinal stromal tumor market was valued at USD 1.15 billion in 2025 and is estimated at USD 1.22 billion in 2026. The market is projected to reach USD 1.99 billion by 2034, representing a 6.3% CAGR during 2026–2034.
Gastrointestinal stromal tumors are mesenchymal neoplasms of the gastrointestinal tract most commonly driven by activating alterations in KIT or PDGFRA. Commercial demand is concentrated in molecularly targeted therapies, diagnostic pathology and longitudinal oncology management because conventional cytotoxic chemotherapy has limited activity in GIST.
The modern treatment pathway is highly genotype dependent. NCI identifies imatinib as first-line therapy for most KIT- and PDGFRA-variant GISTs, while avapritinib is used as first-line therapy for PDGFRA D842V-mutant disease. Sunitinib, regorafenib and ripretinib are used in later-line settings, making sequential targeted therapy the core commercial structure of the market.
The competitive landscape changed materially through recent acquisitions. Ono Pharmaceutical completed the acquisition of Deciphera Pharmaceuticals in June 2024, bringing QINLOCK into Ono’s portfolio, while Sanofi completed the acquisition of Blueprint Medicines in July 2025, adding AYVAKIT and its KIT-focused commercial infrastructure. These transactions have consolidated key mutation-specific and later-line GIST assets within larger pharmaceutical groups.
Source: NCI GIST treatment; NCI approved GIST drugs; Sanofi acquisition of Blueprint; Ono acquisition of Deciphera.
The study defines the global gastrointestinal stromal tumor market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Stomach; Small Intestine; Others |
| By Application | Hospitals; Clinics; Specialized Cancer Treatment Centers; Other End Users |
| By End User | Adult Patients; Pediatric Patients; Geriatric Patients |
| By Mutation Type | KIT Mutations; PDGFRA Mutations; Wild-Type GIST |
| By Treatment Modality | Surgery; Targeted Therapy; Other Therapies |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; France; United Kingdom; Italy; China; Japan; South Korea; India; Australia; Brazil and other relevant markets |
| Key Market Players | Novartis; Pfizer; Bayer; Sanofi / Blueprint Medicines; Ono Pharmaceutical / Deciphera Pharmaceuticals; Sun Pharmaceutical Industries; NATCO Pharma; Johnson & Johnson; Taiho Pharmaceutical; Zai Lab |
The market includes pharmacologic and procedure-related commercial activity directly associated with diagnosis, surgery and systemic treatment of gastrointestinal stromal tumors, with targeted therapies representing the core revenue pool.
General sarcoma therapies without a GIST indication, unrelated gastrointestinal oncology products and supportive medicines used across all cancers are outside the core market boundary.
NCI identifies TKIs as the principal systemic treatment for unresectable, metastatic, recurrent and high-risk disease. Long treatment duration creates a recurring revenue base.
KIT and PDGFRA mutation status directly influence drug choice, dose and expected sensitivity. PDGFRA D842V disease is particularly important because avapritinib provides a mutation-specific first-line option.
Secondary resistance to imatinib is common over time, creating the need for sunitinib, regorafenib, ripretinib and investigational strategies.
Broad generic availability improves access but reduces the commercial value of the foundational treatment, shifting premium value toward mutation-specific and later-line therapies.
GIST is uncommon and often requires coordinated pathology, surgery, oncology and imaging expertise. This concentrates advanced therapy use in high-volume sarcoma centers.
Source: NCI GIST treatment; NCI GIST drugs.
The strongest innovation is moving toward drugs designed for defined KIT or PDGFRA variants rather than broad use across every GIST genotype.
Resistance after sequential TKIs creates demand for new inhibitors with broader activity across secondary KIT mutations.
Sanofi now owns Blueprint Medicines and AYVAKIT, while Ono owns Deciphera and QINLOCK, concentrating specialty GIST assets in larger companies.
Lower-cost imatinib improves affordability in emerging markets and increases the treated population even as it reduces revenue per patient.
Mutation testing increasingly determines first-line and subsequent therapy, making genotype characterization inseparable from modern GIST care.
Source: Sanofi Blueprint acquisition; Ono Deciphera acquisition; NCI.
GIST treatment is a model of precision oncology in which tumor genotype and resistance profile influence therapy sequencing.
Imatinib inhibits KIT and PDGFRA and remains first-line therapy for most susceptible advanced GIST.
Avapritinib is used for PDGFRA exon 18-mutant GIST, including D842V disease that is resistant to imatinib.
Later-line TKIs address progression after earlier therapy and extend systemic treatment duration.
Surgery remains central for resectable localized disease and can be combined with neoadjuvant or adjuvant TKI treatment.
Source: NCI treatment; NCI drug list.
By type, the market is segmented into stomach, small intestine and other primary locations. Stomach-origin GIST remains the leading anatomical segment.
Gastric GIST accounts for the largest share of diagnosed disease and supports the greatest volume of surgery, imaging and targeted therapy.
Small-intestinal GIST is clinically important and can exhibit distinct recurrence and mutational patterns.
Other sites include colon, rectum, esophagus and extra-gastrointestinal presentations.
Stomach-origin disease will remain the largest anatomical segment, while small-intestinal and other sites retain clinically distinct treatment patterns.
By application, the market is segmented into hospitals, clinics, specialized cancer treatment centers and other end users. Hospitals lead through integrated surgery, pathology, imaging and systemic therapy.
Hospitals manage surgery, imaging, pathology and systemic treatment and therefore account for the largest share of comprehensive care.
Oncology clinics provide routine oral TKI management, toxicity monitoring and follow-up.
Sarcoma centers concentrate mutation testing, complex surgery and later-line therapy expertise.
Other settings include research institutions and specialty diagnostic facilities.
Hospitals will remain the largest application, while specialized cancer centers generate disproportionate use of complex molecular and later-line therapy.
By end user, the market is segmented into adult, pediatric and geriatric patients. Adult and older-adult patients dominate because GIST incidence rises with age.
Most treated GIST patients are adults, forming the main commercial population for surgery and targeted therapy.
Pediatric GIST is uncommon and more likely to involve non-KIT/PDGFRA biology, creating specialist treatment needs.
Older adults contribute substantial demand because NCI cites a median diagnosis age in the late sixties.
Adult and geriatric patients will remain the dominant groups, while pediatric GIST requires specialized genomic and multidisciplinary care.
By mutation type, the market is segmented into KIT-mutant, PDGFRA-mutant and wild-type GIST. KIT mutations represent the largest commercial segment.
KIT-mutant GIST represents the principal population treated with imatinib and sequential KIT-directed TKIs.
PDGFRA-mutant disease includes D842V tumors for which avapritinib provides a differentiated targeted option.
Wild-type GIST lacks common KIT/PDGFRA alterations and can be resistant to standard imatinib therapy.
KIT-mutant disease will remain the largest molecular segment, while PDGFRA-targeted treatment and wild-type research sustain precision-oncology innovation.
By treatment modality, the market is segmented into surgery, targeted therapy and other therapies. Targeted therapy is the leading commercial modality.
Long-duration oral TKI treatment drives the largest recurring pharmaceutical value across adjuvant and metastatic care.
Complete resection remains central for localized, technically resectable GIST.
Other approaches include clinical trials, watchful waiting in selected very small tumors and supportive treatment.
Targeted therapy will remain the primary commercial value pool, while surgery continues to define localized-disease management.
Regional demand reflects specialist oncology access, molecular testing and reimbursement for targeted therapy. North America remains the largest market.
The region leads through rapid molecular testing, specialist sarcoma centers and access to multiple approved TKIs.
European sarcoma networks and public healthcare systems support molecular diagnosis and sequential TKI treatment.
China, Japan and South Korea combine rising diagnosis with strong oncology infrastructure and local generic availability.
Growth is constrained by variable reimbursement for newer TKIs despite improving specialist oncology access.
Premium cancer centers provide modern GIST care, while broader access remains uneven.
Source: NCI; NCI drug list.
GIST treatment is tightly linked to approved drug indications and molecular subtype.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| Approved targeted options | NCI lists avapritinib, imatinib, ripretinib, regorafenib and sunitinib among FDA-approved GIST drugs. | Supports multi-line therapy. |
| Genotype-guided treatment | NCI specifically distinguishes PDGFRA D842V disease from other GIST because of differential drug sensitivity. | Makes molecular testing clinically essential. |
| Corporate ownership changes | Sanofi completed Blueprint acquisition in 2025 and Ono completed Deciphera acquisition in 2024. | Changes current commercial ownership of important GIST assets. |
| Rare-disease concentration | GIST represents less than 1% of GI tumors. | Favors specialist-center commercialization and targeted launch strategies. |
Source: NCI drug list; Sanofi; Ono.
Competition is concentrated around targeted-therapy franchises and generic imatinib suppliers. The market has shifted from a simple first-line TKI structure toward mutation-specific and sequential later-line competition.
Imatinib remains the backbone of therapy for most susceptible GIST, although generic competition limits premium pricing.
Sunitinib and regorafenib provide established second- and third-line options.
AYVAKIT and QINLOCK provide differentiated positions in PDGFRA-mutant and heavily pretreated GIST.
July 2025: Sanofi completed the acquisition of Blueprint Medicines, bringing AYVAKIT and its KIT-focused commercial platform into Sanofi.
June 2024: Ono Pharmaceutical completed the acquisition of Deciphera Pharmaceuticals, making Deciphera a wholly owned Ono subsidiary and adding QINLOCK.
Current treatment landscape: NCI continues to identify imatinib as first-line treatment for most KIT/PDGFRA-variant GIST and avapritinib as first-line treatment for PDGFRA D842V-mutant GIST.
Current approved-drug landscape: NCI lists multiple approved GIST therapies spanning first-line through later-line treatment, supporting continued sequential therapy.
Source: Sanofi; Ono; NCI treatment; NCI drugs.
The global gastrointestinal stromal tumor market market is projected to grow from USD 1.22 billion in 2026 to USD 1.99 billion by 2034, at a 6.3% CAGR during 2026–2034. Growth is expected to be supported by longer treatment duration, broader mutation testing and use of newer genotype-specific or later-line TKIs. Generic imatinib will continue to improve access while concentrating incremental value in differentiated therapies.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Mutation testing | Treatment selection increasingly depends on KIT and PDGFRA genotype. | Supports precision therapy. |
| Sequential therapy | Resistance creates demand for multiple lines of TKIs. | Extends treatment value. |
| Generic access | Lower-cost imatinib broadens treated populations. | Supports volume growth. |
| Specialty centers | Rare-disease management remains concentrated in expert centers. | Supports premium launches. |
| Pipeline innovation | Resistance biology remains an active drug-development target. | Creates future opportunities. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global gastrointestinal stromal tumor market landscape.
24LifeScience develops gastrointestinal stromal tumor market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis uses the report’s defined market scope and current NCI treatment evidence together with current corporate ownership information from Sanofi and Ono Pharmaceutical. The headline values follow a 2025 base year, 2026 estimate and 2034 forecast with the displayed CAGR reconciled to the 2026 and 2034 endpoints.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 1.15 billion in 2025 and is estimated at USD 1.22 billion in 2026. It is projected to reach USD 1.99 billion by 2034 at a 6.3% CAGR during 2026–2034.
Stomach-origin GIST is the leading anatomical segment.
Targeted therapy leads because oral TKIs are used across adjuvant, unresectable, metastatic and recurrent disease.
North America is the largest regional market because of advanced molecular testing and broad access to approved targeted therapy.
KIT and PDGFRA mutations influence drug selection, dose and treatment sensitivity.
NCI lists imatinib, sunitinib, regorafenib, ripretinib and avapritinib among approved GIST therapies.
Sanofi owns Blueprint Medicines and AYVAKIT, while Ono Pharmaceutical owns Deciphera and QINLOCK.
The report profiles Novartis, Pfizer, Bayer, Sanofi/Blueprint, Ono/Deciphera and major generic oncology suppliers.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.